Position in GERN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,177,857
-$25,303,272 QoQ
Shares Held
4,045,201
-80.2% QoQ
Ownership
0.630%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#27
of 258 holders
Holding Since
Mar 2023
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in GERN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Point72 Asset Management, L.P. holds $2,243,264,515 across 171 Biotechnology names. GERN ranks #78 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
4,473,478 | $158,316,386 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,587,712 | $135,257,185 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,525,782 | $113,640,243 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
416,516 | $101,950,621 | |
| 5 | LEGN |
Legend Biotech Corp
|
3,076,124 | $88,838,461 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
137,029 | $73,577,721 | |
| 7 | CELC |
Celcuity Inc.
|
650,916 | $68,098,831 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
2,433,168 | $61,559,150 |
All Filings in GERN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,177,857 | 4,045,201 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $30,481,129 | 20,457,134 | Shares | Defined | 2026-05-15 | |
| 2025-06-30 | $13,544,765 | 9,606,217 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $11,331,640 | 7,126,818 | Shares | Defined | 2025-07-21 | |
| 2024-12-31 | $5,270,677 | 1,488,892 | Shares | Defined | 2025-02-14 | |
| 2023-03-31 | $6,495,027 | 2,993,100 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||